The effect of low-dose salicylate treatment on platelet function in patients with renal failure treated with darbopoietin alfa (EPOASA study)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2018-002318-11-DK

Enrollment

Registered

2020-01-09

Start date

2020-01-06

Completion date

Unknown

Last updated

2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uraemia MedDRA version: 20.0 Level: LLT Classification code 10046321 Term: Uraemia of renal origin System Organ Class: 100000004857

Interventions

Trade Name: Hjertemagnyl Pharmaceutical Form: Tablet INN or Proposed INN: ACETYLSALICYLIC ACID CAS Number: 50-78-2 Other descriptive name: Hjertemagnyl Concentration unit: mg milligram(s) Concentratio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic kidney failure stage 5 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 30 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 30

Exclusion criteria

Exclusion criteria: Contraindication to Hjertemagnyl Current beeding or increased bleeding risk Current anticoagulant therapy

Design outcomes

Primary

Measure	Time frame
Main Objective: To determine the effect of darbopoietin alfa on platelet function To determine whether hjertemagnyl affects the effect of darbopoietin alfa on platelet function;Secondary Objective: Not applicable;Primary end point(s): Evaluation at end of each therapeutic interval;Timepoint(s) of evaluation of this end point: 0-4-8-12-16 weeks	—

Secondary

Measure	Time frame
Secondary end point(s): not applicable;Timepoint(s) of evaluation of this end point: 4-8-12-16 weeks	—

Countries

Denmark

Contacts

Public ContactDepartment of medicine

Zealand University hospital

jagh@regionsjaelland.dk

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026